...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The American Journal of Cardiology >Long-Term (3 Years) Outcomes of Ranolazine Therapy for Refractory Angina Pectoris (from the Ranolazine Refractory Registry)
【24h】

Long-Term (3 Years) Outcomes of Ranolazine Therapy for Refractory Angina Pectoris (from the Ranolazine Refractory Registry)

机译：长期（3年）Ranolazine治疗难治性肺结气肺炎的结果（来自Ranolazine Refactory Registerry）

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Ranolazine is approved for patients with chronic stable angina but has not been formally studied in patients with refractory angina pectoris (RAP). Patients with RAP have limited therapeutic options and significant limitations in their quality of life. The Ranolazine Refractory Angina Registry was designed to evaluate the safety, tolerability, and effectiveness of ranolazine in RAP patients in order to expand treatment options for this challenging patient population. Using an extensive prospective database, we enrolled 158 consecutive patients evaluated in a dedicated RAP clinic. Angina class, medications, major adverse cardiac events including death, myocardial infarction, and revascularization were obtained at 12, 24, and 36 months. At 3 years, 95 (60%) patients remained on ranolazine. A >= 2 class improvement in angina was seen in 48% (38 of 80 patients with known Canadian Cardiovascular Society class) of those who remained on ranolazine. Discontinuation due to side effects, ineffectiveness, cost, and progression of disease were the principle reasons for discontinuation, but primarily occurred within the first year. In conclusion, ranolazine is an effective antianginal therapy at 3-year follow-up in patients with RAP and may reduce cardiac readmission. (C) 2020 Published by Elsevier Inc.
机译：雷诺嗪被批准用于慢性稳定型心绞痛患者，但尚未对难治性心绞痛（RAP）患者进行正式研究。RAP患者的治疗选择有限，生活质量也有很大限制。雷诺嗪难治性心绞痛登记册旨在评估雷诺嗪对RAP患者的安全性、耐受性和有效性，以扩大这一具有挑战性的患者群体的治疗选择。使用广泛的前瞻性数据库，我们招募了158名在专门的RAP诊所接受评估的连续患者。在12个月、24个月和36个月时获得心绞痛分级、药物、主要不良心脏事件，包括死亡、心肌梗死和血运重建。3年后，95名（60%）患者仍在服用雷诺嗪。在继续服用雷诺嗪的患者中，48%（80名已知加拿大心血管协会等级的患者中有38名）的心绞痛改善程度大于等于2级。由于副作用、无效性、费用和疾病进展而停药是停药的主要原因，但主要发生在第一年内。总之，雷诺嗪是RAP患者3年随访的有效抗心绞痛药物，可能会减少心脏再入院。（C） 2020年由爱思唯尔公司出版。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号